17,400 Shares in Rocket Pharmaceuticals, Inc. $RCKT Purchased by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 17,400 shares of the biotechnology company’s stock, valued at approximately $43,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Victory Capital Management Inc. raised its stake in Rocket Pharmaceuticals by 16.1% during the first quarter. Victory Capital Management Inc. now owns 11,929 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 1,658 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Rocket Pharmaceuticals by 8.4% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 21,885 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 1,689 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Rocket Pharmaceuticals by 10.7% during the first quarter. China Universal Asset Management Co. Ltd. now owns 21,388 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 2,059 shares during the period. HighTower Advisors LLC raised its stake in Rocket Pharmaceuticals by 16.6% during the first quarter. HighTower Advisors LLC now owns 20,700 shares of the biotechnology company’s stock worth $138,000 after acquiring an additional 2,952 shares during the period. Finally, Arizona State Retirement System grew its position in shares of Rocket Pharmaceuticals by 15.3% during the first quarter. Arizona State Retirement System now owns 22,852 shares of the biotechnology company’s stock worth $152,000 after acquiring an additional 3,026 shares during the last quarter. Institutional investors and hedge funds own 98.39% of the company’s stock.

Rocket Pharmaceuticals Trading Up 2.9%

Rocket Pharmaceuticals stock opened at $3.85 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.39 and a current ratio of 6.39. The firm has a market cap of $415.42 million, a price-to-earnings ratio of -1.53 and a beta of 0.60. Rocket Pharmaceuticals, Inc. has a 1 year low of $2.19 and a 1 year high of $18.17. The firm’s 50 day moving average price is $3.40 and its two-hundred day moving average price is $3.98.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.02). During the same period in the previous year, the business posted ($0.74) EPS. On average, research analysts predict that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Chardan Capital restated a “buy” rating and set a $11.00 price target on shares of Rocket Pharmaceuticals in a research report on Tuesday, October 14th. Cantor Fitzgerald dropped their price target on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Rocket Pharmaceuticals in a research note on Saturday. Leerink Partners dropped their price target on shares of Rocket Pharmaceuticals from $9.00 to $7.00 and set a “market perform” rating on the stock in a research note on Friday, October 3rd. Finally, Canaccord Genuity Group dropped their price target on shares of Rocket Pharmaceuticals from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, July 25th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Rocket Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $16.67.

Insider Buying and Selling at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, General Counsel Martin Wilson sold 12,109 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $3.02, for a total value of $36,569.18. Following the transaction, the general counsel owned 137,054 shares in the company, valued at approximately $413,903.08. The trade was a 8.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Elisabeth Bjork purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, August 27th. The stock was acquired at an average price of $3.41 per share, for a total transaction of $34,100.00. Following the transaction, the director owned 40,000 shares of the company’s stock, valued at $136,400. The trade was a 33.33% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 64,368 shares of company stock worth $221,675. 24.76% of the stock is owned by corporate insiders.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.